
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences is poised for continued success, with strong performance in their core revenue segments and solid earnings growth. Their recent 2Q results beat expectations and led to an increase in their revenue outlook for FY26. Despite difficult 2H comps, the company is maintaining its growth trajectory and has potential for further expansion through new product launches and opportunities in adjacent markets. Their strong financials, innovative products, and sustainable practices make them a clear leader in the competitive medical device industry.
Bears say
Edwards Lifesciences is currently experiencing growth in revenue in key products, including TAVR and TMTT. However, potential growth headwinds driven by macro factors, slower adoption of TAVR, and increased competition could hinder the company's overall performance. Furthermore, there is a risk for potential setbacks in R&D efforts or clinical trials, as well as external factors such as staffing shortages that could impact the company's financials. These risks could lead to a downside scenario for the stock and should be closely monitored by investors.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares